Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Psoriasis: full-pipeline trial registry
26 of 127 indexed Psoriasis trials are currently recruiting.
Corpus placement: #93 of 28,707 conditions by registered trial count.
127 US clinical trials · 26 currently recruiting · #93 of 28,707 conditions by registered trial count
Psoriasis: 127 US clinical trials tracked, 26 recruiting.
Psoriasis is the subject of 127 registered US clinical trials on ClinicalTrials.gov, 26 of them currently open to new participants. 50 are in Phase 3-4 (later-stage) and 36 in Phase 1-2 (earlier-stage). The most active sponsor is Bristol-Myers Squibb, running 8 of these trials.
Enrollment posture brief
Registry condition psoriasis
OPEN 26 | RECR 20% | LATE 50 | EARLY 36 | RANK #93 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Healthy (21% recruiting · 1,096 trials)
Psoriasis lists 26 open slots (20% of 127 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Psoriasis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Psoriasis is recruiting below its size-band peers.
26 of 127 indexed trials (20.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Psoriasis trials is spread across many organizations.
Bristol-Myers Squibb accounts for 8 of 127 trials (6.3%). 65 distinct sponsors appear on at least one study for this condition label.
-
Typical Psoriasis enrolment sits around 84 participants.
Median target enrolment is 84 among the 126 trials that report a genuine target (sentinel values excluded). 68 of those (54%) plan for fewer than 100 participants.
-
Psoriasis research is mostly interventional.
101 interventional and 26 observational studies make up this index (79.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
127 total, page 1 of 3
IMPACT - AndHealth Autoimmune Research Registry
AndHealth
NCT05883371
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
Bristol-Myers Squibb
NCT05744466
Psorcast Mobile Study
Sage Bionetworks
NCT05621369
Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis
University of Pennsylvania
NCT05908240
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
National Cancer Institute (NCI)
NCT03816345
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04864886
Skin Microbial Ecology in Atopic Dermatitis
University of Rochester
NCT04170244
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
University of California, San Diego
NCT02103361
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Eli Lilly and Company
NCT06857942
Multi-Center PAMPA Study
NYU Langone Health
NCT05004727
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
Jiangsu Hansoh Pharmaceutical Co.
NCT06846710
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
M.D. Anderson Cancer Center
NCT04751396
A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis
Sirt3
NCT07471048
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
SFA Therapeutics
NCT05642182
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
University Hospitals Cleveland Medical Center
NCT05270733
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
Bausch Health Americas
NCT03987763
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
Bausch Health Americas
NCT03988439
Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors
University Hospitals Cleveland Medical Center
NCT06399432
An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
Psoriasis Treatment Center of Central New Jersey
NCT03392337
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Psoriasis Treatment Center of Central New Jersey
NCT03827876
Duobrii in Combination With Biologics
Psoriasis Treatment Center of Central New Jersey
NCT04119102
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
Psoriasis Treatment Center of Central New Jersey
NCT04347473
Taltz in Combination With Enstilar for Psoriasis
Psoriasis Treatment Center of Central New Jersey
NCT04372277
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
Arcutis Biotherapeutics
NCT07340216
Regulation of Inflammatory Genes in Psoriasis
University of Alabama at Birmingham
NCT03125655
Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
University of California, Davis
NCT06574178
Psoriasis Longitudinal Assessment and Registry
Janssen Scientific Affairs
NCT00508547
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Target PharmaSolutions
NCT03661866
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
Alumis
NCT06846541
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
Bristol-Myers Squibb
NCT04036435
OTIS Cimzia Pregnancy Registry
University of California, San Diego
NCT01797224
A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring
Bristol-Myers Squibb
NCT06710470
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Eli Lilly and Company
NCT06588283
Apremilast Pregnancy Exposure Registry
University of California, San Diego
NCT02775500
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
AbbVie
NCT04862286
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
Janssen Research & Development
NCT03451851
Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis
Ohio State University
NCT05590247
Deucravacitinib Adherence Study
Wake Forest University Health Sciences
NCT05570955
Use of Transcutaneous Electrical Nerve Stimulation for Reducing Biologic Injection Site Pain(TENS Study)
Wake Forest University Health Sciences
NCT04058652
Risankizumab Long-term Remission Study
Jaehwan Kim
NCT04630652
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
Bausch Health Americas
NCT03240809
A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)
Genentech
NCT00096928
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
Eli Lilly and Company
NCT01474512
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)
Eli Lilly and Company
NCT01597245
Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments
Northwestern University
NCT03051347
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
NCT01276639
A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis
Astellas Pharma
NCT00293891
Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles
National Cancer Institute (NCI)
NCT00005781
Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
Maruho North America
NCT01878461
A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Amgen
NCT04761627
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 20 |
| Phase 2 | 16 |
| Phase 3 | 26 |
| Phase 4 | 24 |
Top Sponsors
Named interventions
Most-linked intervention names on Psoriasis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Psoriasis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Psoriasis page
127 registered trials, 26 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 26 Psoriasis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bristol-Myers Squibb sponsors the most Psoriasis trials on record, review their full trial history before evaluating a specific study. See Bristol-Myers Squibb's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Psoriasis condition card totals 127 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.